Sumitomo Pharma Co. Ltd. has patented aminomethylcyclohexane derivatives acting as muscarinic M4 receptor antagonists. As such, they are described as potentially useful for the treatment of neurodegenerative diseases, cerebrovascular disorders, brain injury, movement and psychiatric disorders.